补肾疏肝方对人肺腺癌A549细胞及小鼠Lewis肺癌抑制作用的实验研究
|
摘要
背景与目的：
观察补肾疏肝方含药血清对人肺腺癌A549细胞生长的影响及补肾疏肝方对Lewis肺癌荷瘤小鼠免疫及内分泌的影响并研究其中可能存在的机制。
方法：
补肾疏肝方含药血清对人肺腺癌A549细胞生长的影响实验。选取健康的SD大鼠30只,随机分为五组：模型组、DDP组、补肾疏肝方低剂量组、补肾疏肝方中剂量组、补肾疏肝方高剂量组,每组6只。模型组给予生理盐水4ml/天；DDP组给予0.5mg/mlDDP液2ml,分别于第1、3、5天腹腔注射；补肾疏肝方低剂量组给予中药4ml/天灌胃(1.75g/ml共计含生药7g)；补肾疏肝方低剂量组给予中药4ml/天灌胃(3.5g/ml共计含生药14g)；补肾疏肝方低剂量组给予中药4ml/天灌胃(5.25g/ml共计含生药21g)。共干预5天。第5天干预2小时后腹主动脉取血,制备大鼠含药血清,-20℃冰箱保存。临用时配制为含血清10%的培养液培养细胞,MTT法测OD值,观察补肾疏肝方含药血清对细胞生长的抑制作用。
补肾疏肝方对Lewis肺癌荷瘤小鼠免疫及内分泌的影响实验。植瘤5天后,于腋下可触及约5mm*5mm肿块。选取荷瘤成功的C57BL/6小鼠40只,随机分为四组：模型组、DDP (cisplatin)组、补肾疏肝方组、DDP+中药组。每组10只。模型组给予0.9%NaCl灌胃0.4ml/天,同时于第1、3、5天腹腔注射0.9%NaCl0.5ml。DDP组小鼠分别在实验第1、3、5天给予腹腔注射0.5mlDDP(0.2mg/m1)溶液,并给予0.9%NaCl灌胃0.4ml/天。补肾疏肝方组给予中药灌胃0.4ml/天(1.75g/ml共计含生药0.7g),同时于第1、3、5天腹腔注射0.9%NaCl0.5ml。DDP+中药组给予每日中药灌胃,同时分别于第1、3、5天腹腔注射DDPO.5ml。共干预14天。每日记录小鼠精神状态、活动状况、毛发饮食及大小便情况,每天称取小鼠体重,测肿瘤体积。于第15天摘眼球取血,剥取肿瘤称重,计算抑瘤率、肺转移抑制率等。采取酶联免疫吸附(ELISA)的方法检测血清IL-2、IL-10、E2、T含量。
结果：
1、体外实验中,与模型组相比,中药低剂量组48h、72h,中剂量组、高剂量组、顺铂组均可以抑制肺腺癌A549细胞生长,差异明显(p<0.01),并呈时间-剂量依赖性。高剂量组与顺铂组差异不明显(p>0.05)。
2、体内实验中,与模型组相比,各用药组均能抑制肿瘤生长,差异明显(p<0.01)。与中药组相比较,中西医结合组平均瘤重显著降低,有统计学意义(p<0.05)。
3、与模型组相比,其余各组均能显著抑制肿瘤的自发性肺转移(p<0.05或p<0.01)。
4、实验结束后,与模型组相比,DDP组小鼠体重均明显减轻,差异显著(p<0.05)；中药组及DDP+中药组小鼠体重均明显增加,差异显著(p<0.05)。与模型组相比,各用药组小鼠肿瘤体积明显较小(p<0.05)
5、与模型组相比,各组血清IL-2含量均明显增高,差异显著(p<0.01);与DDP组相比,DDP+中药组明显增高(p<0.01)。与模型组相比,各用药组IL-10显著降低(p<0.01);与中药组和顺铂组相比,中西医结合组IL-10均显著降低(p<0.01)；与顺铂组相比,中药组IL-10降低有统计学意义(p<0.01)。
6、与模型组相比,各用药组E2显著降低(p<0.01)；与顺铂组和中药组相比,中西医结合组E：表达降低有统计学意义(p<0.01)。与模型组相比,各用药组T显著升高;与顺铂组和中药组相比,中西医结合组T表达升高有统计学意义(p<0.01)。与模型组相比,各用药组E2/T显著降低(p<0.01)；与顺铂组和中药组相比,中西医结合组E2/T表达降低有统计学意义(p<0.01)。
结论：
1、补肾疏肝方含药血清可以抑制肺腺癌A549细胞生长,并呈时间-剂量依赖关系。
2、补肾疏肝方可以显著抑制小鼠Lewis市癌生长,并与顺铂联合有协同作用。
3、补肾疏肝方可以调节荷瘤小鼠体内免疫及内分泌平衡,这可能是本方抑制肿瘤生长的机制之一。
4、补肾疏肝方可以提高小鼠生活质量,减轻化疗引起的毒副作用。
Objective:
To investgate the effect of Bushen Shugan(BSSG) formula on immune function and endocrine system of lewis lung cancer mice and the effect of serum containing BSSG on the proliferation of A549cells and discuss the possible underlying mechanism.
Methods:
In Vitro Experiment.30healthy SD mice were randomly divided into five groups:model control group、DDP group、low-dose group、middle-dose group、 high-dose group of serum containing BSSG. Model control group was given saline4ml by intragastric administration every day; DDP group was given cisplatin solution2ml(containing DDP1mg)by the way of intraperitoneal injection on the first day、the third day and the fifth day; low-dose group was given BuShenShuGan formula4ml/d (containing crude chinese herb7g) by intragastric administration; middle-dose group was given BuShenShuGan formula4ml/d (containing crude chinese herb14g) by intragastric administration; high-dose group was given BuShenShuGan formula4ml/d (containing crude chinese herb21g) by intragastric administration; all the treaments lasted5days.At last,the mice blood were collected by puncturing the aorta abdominalis2hours after treaments on the fifth day.The serum containing BSSG was made,and store in the refrigerator of-20℃.We can observe the effect of serum containing BSSG on the proliferation of A549cells.
In Vivo Experiment.40C57BL/6mice that had been successfully transplanted Lewis lung cancer model were randomly divided into four groups:model control group、DDP group、BSSG group、BSSG combined with DDP group. Model control group was given saline0.4ml by intragastric administration every day, and the same time was given saline0.5ml by the way of intraperitoneal injection on the first day、 the third day and the fifth day;DDP group was given cisplatin solution0.5ml (containing DDP0.1mg) by the way of intraperitoneal injection on the first day、the third day and the fifth day,and the same time was given saline0.4ml by intragastric administration every day; BSSG group was given BuShenShuGan formula0.4ml/d (containing crude chinese herb0.7g) by intragastric administration, and the same time was given saline0.5ml by the way of intraperitoneal injection on the first day、 the third day and the fifth day; BSSG combined with DDP group was given BuShenShuGan formula by intragastric administration and cisplatin solution by intraperitoneal injection which was the same as BSSG group and DDP group;all the treaments lasted14days. We observed the mental state、diet and activities of mice everyday, and measured body weight and tumor volume of mice every two days. At last,all the mice blood were collected by taking off the eyeballs on the fifteenth day, and tumor weight and numbers of spontaneous lung metastasis were also measured.The concentration of serum IL-2、IL-10、E2and T were measured by ELISA.
Results:
1、In vitro experiment, compared with model control group, low-dose group of BSSG(48h、72h)、middle-dose group、high-dose group and DDP group can inhibit the proliferation of A549cells(p<0.01),which has the dose effect and time effect. It is almost no difference between high-dose group and DDP group (p>0.05)
2、In Vivo Experiment.Compared with model control group, the other treatment group could significantly inhibit tumor growth, and the difference was significant (p<0.01). Compared with BSSG group, the average tumor weight of BSSG combined with DDP group decreased significantly (p＜O.05).
3、Compared with model control group, the other treatment group could significantly inhibit the spontaneous lung metastasis (p<0.05or p<0.01).
4、After the experiment finished, compared with model control group, the weight of DDP group decreased (p<0.05); BSSG group and BSSG combined with DDP group were significantly increased (p<0.05), there was no difference between Chinese herbal medicine group and combined group (p>0.05). Compared with model control group, tumor volume of every treatment group was significantly smaller (p<0.05); compared with DDP group and BSSG group, though the tumor volume of combined group was smaller, the difference was not significantly(p>0.05).
5、Compared with model group, the blood serum IL-2of all treatment groups increased significantly (p<0.01); compared with DDP group, BSSG combined with DDP group increased significantly (p<0.01). Compared with model control group, the blood serum IL-10of the treatment groups significantly decreased (p<0.01); compared with DDP group, the blood serum IL-10of BSSG group was significantly decreased (p<0.05).
6、Compared with model control group, the blood serum E2of all treatment groups decreased significantly (p<0.01); compared with DDP group and BSSG group, the blood serum E2of BSSG combined with DDP group decreased significantly (p<0.01). Compared with model control group, the blood serum T of all treatment groups increased significantly (p<0.01); compared with DDP group and BSSG group, the blood serum T of BSSG combined with DDP group increased significantly (p<0.01). Compared with model control group, the blood serum E2/T of all treatment groups decreased significantly (p<0.01); compared with DDP group and BSSG group, the blood serum E2/T of BSSG combined with DDP group decreased significantly (p<0.01).
Conclusion:
1、Serum containing BSSG can inhibit the proliferation of A549cells, which has the dose effect and time effect.
2、BuShenShuGan Formula could significantly inhibit growth and spontaneous lung metastasis of Lewis lung cancer, and there was synergistic effect with cisplatin.
3、BSSG Formula can make an effect on the level of blood serum IL-2、IL-10、E2and T.It can improve the functions of immunity and regulate internal secretion, and this may be one of the mechanisms of the inhibition of tumor growth.
4、BuShenShuGan Formula could improve the quality of the mice life, reduce the side effects caused by chemotherapy such as weight loss and so on.
观察补肾疏肝方含药血清对人肺腺癌A549细胞生长的影响及补肾疏肝方对Lewis肺癌荷瘤小鼠免疫及内分泌的影响并研究其中可能存在的机制。
方法：
补肾疏肝方含药血清对人肺腺癌A549细胞生长的影响实验。选取健康的SD大鼠30只,随机分为五组：模型组、DDP组、补肾疏肝方低剂量组、补肾疏肝方中剂量组、补肾疏肝方高剂量组,每组6只。模型组给予生理盐水4ml/天；DDP组给予0.5mg/mlDDP液2ml,分别于第1、3、5天腹腔注射；补肾疏肝方低剂量组给予中药4ml/天灌胃(1.75g/ml共计含生药7g)；补肾疏肝方低剂量组给予中药4ml/天灌胃(3.5g/ml共计含生药14g)；补肾疏肝方低剂量组给予中药4ml/天灌胃(5.25g/ml共计含生药21g)。共干预5天。第5天干预2小时后腹主动脉取血,制备大鼠含药血清,-20℃冰箱保存。临用时配制为含血清10%的培养液培养细胞,MTT法测OD值,观察补肾疏肝方含药血清对细胞生长的抑制作用。
补肾疏肝方对Lewis肺癌荷瘤小鼠免疫及内分泌的影响实验。植瘤5天后,于腋下可触及约5mm*5mm肿块。选取荷瘤成功的C57BL/6小鼠40只,随机分为四组：模型组、DDP (cisplatin)组、补肾疏肝方组、DDP+中药组。每组10只。模型组给予0.9%NaCl灌胃0.4ml/天,同时于第1、3、5天腹腔注射0.9%NaCl0.5ml。DDP组小鼠分别在实验第1、3、5天给予腹腔注射0.5mlDDP(0.2mg/m1)溶液,并给予0.9%NaCl灌胃0.4ml/天。补肾疏肝方组给予中药灌胃0.4ml/天(1.75g/ml共计含生药0.7g),同时于第1、3、5天腹腔注射0.9%NaCl0.5ml。DDP+中药组给予每日中药灌胃,同时分别于第1、3、5天腹腔注射DDPO.5ml。共干预14天。每日记录小鼠精神状态、活动状况、毛发饮食及大小便情况,每天称取小鼠体重,测肿瘤体积。于第15天摘眼球取血,剥取肿瘤称重,计算抑瘤率、肺转移抑制率等。采取酶联免疫吸附(ELISA)的方法检测血清IL-2、IL-10、E2、T含量。
结果：
1、体外实验中,与模型组相比,中药低剂量组48h、72h,中剂量组、高剂量组、顺铂组均可以抑制肺腺癌A549细胞生长,差异明显(p<0.01),并呈时间-剂量依赖性。高剂量组与顺铂组差异不明显(p>0.05)。
2、体内实验中,与模型组相比,各用药组均能抑制肿瘤生长,差异明显(p<0.01)。与中药组相比较,中西医结合组平均瘤重显著降低,有统计学意义(p<0.05)。
3、与模型组相比,其余各组均能显著抑制肿瘤的自发性肺转移(p<0.05或p<0.01)。
4、实验结束后,与模型组相比,DDP组小鼠体重均明显减轻,差异显著(p<0.05)；中药组及DDP+中药组小鼠体重均明显增加,差异显著(p<0.05)。与模型组相比,各用药组小鼠肿瘤体积明显较小(p<0.05)
5、与模型组相比,各组血清IL-2含量均明显增高,差异显著(p<0.01);与DDP组相比,DDP+中药组明显增高(p<0.01)。与模型组相比,各用药组IL-10显著降低(p<0.01);与中药组和顺铂组相比,中西医结合组IL-10均显著降低(p<0.01)；与顺铂组相比,中药组IL-10降低有统计学意义(p<0.01)。
6、与模型组相比,各用药组E2显著降低(p<0.01)；与顺铂组和中药组相比,中西医结合组E：表达降低有统计学意义(p<0.01)。与模型组相比,各用药组T显著升高;与顺铂组和中药组相比,中西医结合组T表达升高有统计学意义(p<0.01)。与模型组相比,各用药组E2/T显著降低(p<0.01)；与顺铂组和中药组相比,中西医结合组E2/T表达降低有统计学意义(p<0.01)。
结论：
1、补肾疏肝方含药血清可以抑制肺腺癌A549细胞生长,并呈时间-剂量依赖关系。
2、补肾疏肝方可以显著抑制小鼠Lewis市癌生长,并与顺铂联合有协同作用。
3、补肾疏肝方可以调节荷瘤小鼠体内免疫及内分泌平衡,这可能是本方抑制肿瘤生长的机制之一。
4、补肾疏肝方可以提高小鼠生活质量,减轻化疗引起的毒副作用。
Objective:
To investgate the effect of Bushen Shugan(BSSG) formula on immune function and endocrine system of lewis lung cancer mice and the effect of serum containing BSSG on the proliferation of A549cells and discuss the possible underlying mechanism.
Methods:
In Vitro Experiment.30healthy SD mice were randomly divided into five groups:model control group、DDP group、low-dose group、middle-dose group、 high-dose group of serum containing BSSG. Model control group was given saline4ml by intragastric administration every day; DDP group was given cisplatin solution2ml(containing DDP1mg)by the way of intraperitoneal injection on the first day、the third day and the fifth day; low-dose group was given BuShenShuGan formula4ml/d (containing crude chinese herb7g) by intragastric administration; middle-dose group was given BuShenShuGan formula4ml/d (containing crude chinese herb14g) by intragastric administration; high-dose group was given BuShenShuGan formula4ml/d (containing crude chinese herb21g) by intragastric administration; all the treaments lasted5days.At last,the mice blood were collected by puncturing the aorta abdominalis2hours after treaments on the fifth day.The serum containing BSSG was made,and store in the refrigerator of-20℃.We can observe the effect of serum containing BSSG on the proliferation of A549cells.
In Vivo Experiment.40C57BL/6mice that had been successfully transplanted Lewis lung cancer model were randomly divided into four groups:model control group、DDP group、BSSG group、BSSG combined with DDP group. Model control group was given saline0.4ml by intragastric administration every day, and the same time was given saline0.5ml by the way of intraperitoneal injection on the first day、 the third day and the fifth day;DDP group was given cisplatin solution0.5ml (containing DDP0.1mg) by the way of intraperitoneal injection on the first day、the third day and the fifth day,and the same time was given saline0.4ml by intragastric administration every day; BSSG group was given BuShenShuGan formula0.4ml/d (containing crude chinese herb0.7g) by intragastric administration, and the same time was given saline0.5ml by the way of intraperitoneal injection on the first day、 the third day and the fifth day; BSSG combined with DDP group was given BuShenShuGan formula by intragastric administration and cisplatin solution by intraperitoneal injection which was the same as BSSG group and DDP group;all the treaments lasted14days. We observed the mental state、diet and activities of mice everyday, and measured body weight and tumor volume of mice every two days. At last,all the mice blood were collected by taking off the eyeballs on the fifteenth day, and tumor weight and numbers of spontaneous lung metastasis were also measured.The concentration of serum IL-2、IL-10、E2and T were measured by ELISA.
Results:
1、In vitro experiment, compared with model control group, low-dose group of BSSG(48h、72h)、middle-dose group、high-dose group and DDP group can inhibit the proliferation of A549cells(p<0.01),which has the dose effect and time effect. It is almost no difference between high-dose group and DDP group (p>0.05)
2、In Vivo Experiment.Compared with model control group, the other treatment group could significantly inhibit tumor growth, and the difference was significant (p<0.01). Compared with BSSG group, the average tumor weight of BSSG combined with DDP group decreased significantly (p＜O.05).
3、Compared with model control group, the other treatment group could significantly inhibit the spontaneous lung metastasis (p<0.05or p<0.01).
4、After the experiment finished, compared with model control group, the weight of DDP group decreased (p<0.05); BSSG group and BSSG combined with DDP group were significantly increased (p<0.05), there was no difference between Chinese herbal medicine group and combined group (p>0.05). Compared with model control group, tumor volume of every treatment group was significantly smaller (p<0.05); compared with DDP group and BSSG group, though the tumor volume of combined group was smaller, the difference was not significantly(p>0.05).
5、Compared with model group, the blood serum IL-2of all treatment groups increased significantly (p<0.01); compared with DDP group, BSSG combined with DDP group increased significantly (p<0.01). Compared with model control group, the blood serum IL-10of the treatment groups significantly decreased (p<0.01); compared with DDP group, the blood serum IL-10of BSSG group was significantly decreased (p<0.05).
6、Compared with model control group, the blood serum E2of all treatment groups decreased significantly (p<0.01); compared with DDP group and BSSG group, the blood serum E2of BSSG combined with DDP group decreased significantly (p<0.01). Compared with model control group, the blood serum T of all treatment groups increased significantly (p<0.01); compared with DDP group and BSSG group, the blood serum T of BSSG combined with DDP group increased significantly (p<0.01). Compared with model control group, the blood serum E2/T of all treatment groups decreased significantly (p<0.01); compared with DDP group and BSSG group, the blood serum E2/T of BSSG combined with DDP group decreased significantly (p<0.01).
Conclusion:
1、Serum containing BSSG can inhibit the proliferation of A549cells, which has the dose effect and time effect.
2、BuShenShuGan Formula could significantly inhibit growth and spontaneous lung metastasis of Lewis lung cancer, and there was synergistic effect with cisplatin.
3、BSSG Formula can make an effect on the level of blood serum IL-2、IL-10、E2and T.It can improve the functions of immunity and regulate internal secretion, and this may be one of the mechanisms of the inhibition of tumor growth.
4、BuShenShuGan Formula could improve the quality of the mice life, reduce the side effects caused by chemotherapy such as weight loss and so on.
引文
[1]李龙芸.肺癌[J].癌症进展杂志,2005,3(2)：114-115
[2]张培彤,于明谓,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7)：702-705
[3]张培彤,于明薇,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7)：702-705
[4]刘嘉湘.中医药维护癌症患者生存质量的作用[J].中华肿瘤杂志,2002,24(3)：309-310
[5]林丽珠,周岱翰,郑心婷.中医药提高晚期非小细胞肺癌患者生存质量的临床观察[J].中国中西医结合杂志,2006,26(5)：389-393
[6]刘源,王淑玲.补肾散结方联合GP方案治疗晚期非小细胞肺癌临床疗效观察[J].中华中医药杂志,2011,26(4)：864-867
[7]章静波,张世馥,黄东阳等.组织和细胞培养技术[M].北京：人民卫生出版社,2002,9-144
[8]符慧群,唐雪元,潘宇亮.川芍嗓和顺铂联用对小鼠Lewis扛癌生长及转移的抑制作用[J].南华大学学报医学版,2008,36(1)：46-49
[9]靳福鹏,张梅,李平等.益气养阴解毒方对小鼠Lewis肺癌生长抑制作用的实验研究[J].临床肺科杂志,2011,16(1)：72-74
[10]Zhou XD,Cai WQ, Cao HW.Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer [J].Chin J Cancer,2002,21(3):259-262
[11]Stabile LP, Davis ALG, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and (3 and show biological responses to estrogen [J].Cancer Res,2002,62:2141～2150
[12]姚榛祥,唐时森.胎儿乳腺的雌激素受体与乳腺癌[J].中华肿瘤杂志,1991,13(5)：342-343
[13]陈明伟,胡国瑛.双抗夹心法检测肺癌血清激素水平的变化[J].西安医科大学学报,1999,20(2)：202-204
[14]武翠华,罗南萍,牛爱军等.肺癌和食管癌患者血清性激素水平的观察.实用医药杂志,2004,21(4)：324-325
[15]孙继萍,肖伟.Th1/Th2状态与肿瘤[J].实用医药杂志,2004,21(12)：1127-1129
[16]张圣林,邱法波,吴力群.Th1/Th2偏移与恶性肿瘤关系的研究进展[J].细胞与分子免疫学杂志,2005,21(21)：113-114,117
[17]王长印,李萍,董振芳,等.Th1/Th2细胞模式与肿瘤相关性的探讨[J].山东医药,2011,51(31)：25-26
[18]Wynder E. L. The past, present, and future of the prevention of lung cancer. Cancer Epidemiol. Biomark. Prev.,1998,7:735～748
[19]Baldini E. H., Strauss G M. Women and lung cancer:waiting to exhale. Chest,1997,112: 229～239
[20]Shriver S. P., Bourdeau H. A., Gubish C. T., Tirpak D. L., Davis A. L., Luketich J. D., Siegfried J. M. Sex-specific expression of gastrin-releasing peptide receptor:relationship to smoking history and risk of lung cancer. J. Natl. Cancer Inst. (Bethesda),2000,92:24～33
[21]Zang E. A., Wynder E. L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl. Cancer Inst. (Bethesda),1996,88:183～192
[22]Slatore C G, Chien JW, Au DH, et al.Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study [J]. J Clin Oncol,2010,28:1540～1546
[23]岳玲.肺癌及肺癌伴男性乳房发育者血清性激素水平检测及其临床意义[J].安徽医科大学学报,1998,33(2)：140-141.
[24]陈国安,杨得昌,何积银.肺癌患者血中性激素、皮质醇及癌胚抗原水平的研究.陕西医学,1992,21(12)：710-712
[25]陈名声,徐焰,郝晓柯,等.血清性激素的水平对男性肺癌患者诊断的意义.中国肺癌杂志,2005,8：300-303
[26]顾玉兰,张子文,李璐等.肺癌患者血清性激素水平的变化及意义[J].中国实用医药,2010,5(1)：7-8
[27]徐袁秋,许会军.非小细胞肺癌患者血清性激素的变化.河北医药,2011,33(20)：3050-3052
[28]CHEN G G, ZENG Q, TSE G M. Estrogen and its receptors incancer[J]. Med Res Rev, 2008,28 (6):954～974
[29]Lu Q, Nakmura J, Savinov A, et al. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology,1996,137(7):3061～3068
[30]周向东,曹红伟,蔡文琴.男性肺癌患者外周血性激素水平的测定及其临床意义[J].中国肺癌杂志,2001,4(4)：290-292
[31]Thomas L, Doyle L, Edelman M (2005) Lung cancer in women:emerging differences in epidemiology, biology, and therapy. Chest 128:370～381
[32]Gasperino J, Rom W (2004) Gender and lung cancer. Clin Lung Cancer 5:353～359
[33]Stabile L P, Davis A L, Gubish C T, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen[J]. Cancer Res,2002,62(7):2141～2150
[34]Canver C C, Memoli V A, Vanderveer P L, et al. Sex hormone receptors in non-small-cell lung cancer in human beings[J]. J Thorac Cardiovasc Surg,1994,108(1):153～157
[35]邹建军,陈华江,高勇,等.雌激素和孕激素受体在非小细胞肺癌中的的表达[J].中国肿瘤临床,2004,31(19)：1108-1110
[36]李青山,冯威健,赵晓明,等.雌、孕激素受体与P-糖蛋白在肺癌中的表达及其意义[J].临床肿瘤学杂志,2003,8(4)：248-250
[37]闫明,陈小兵,王淑玲,等.雌激素和雄激素受体在肺癌中的表达[J].中国肺癌杂 志,2008,11(1)：126-129
[38]郑军,姚榛祥.三苯氧胺对乳腺癌细胞凋亡和耐药性的影响[J].中华肿瘤杂志,2000,22(1)：55-57
[39]刘延鹏,李玲,潘祥林,等.三苯氧胺联合化疗治疗恶性胶质瘤[J].中国神经精神疾病杂志,2007,33(8)：503-504
[40]宋丽华,肖洲生,周宏濒.植物性雌激素的研究进展[J].国外医学(药学分册),2003,30(1)：25-29
[41]张雯.植物性雌激素化学成分及其药理研究[J].中国现代实用医学杂志,2005,4(8)：50-54
[42]柳林,张玉珍,刘欣.植物性雌激素对更年期症状及癌症的临床作用[J].潍坊医学院学报,2003,25(6)：462-463
[43]王妹妹,范林军.植物性雌激素摄入与乳腺癌的关联[J].中华乳腺病杂志(电子版),2008,2(2)：238-248
[44]夏仲元,潘琳,李鸿,等.疏肝通络方干预乳腺增生大鼠的实验研究[J].北京中医药大学学报,2009,32(12)：834-838
[45]Yamamura M, Modlin RL, Ohmen JD, et al. Local exp ression of anti-inflammatory cytokines in cancer. [J] Clin Invest,1993,91:1005～1010
[46]Huang M, W ang J, L ee P, et al. Human non small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res,1995,55:3847-3853
[47]刘杰,田志刚,冯进波,等.人肿瘤细胞中Th2类细胞因子的强势表达[J].中华肿瘤杂志,1998,(2)：105
[48]王敬然,董英辉.生物免疫制剂及参芪扶正注射液对NF-κB活性的影响[J].实用肿瘤杂志,2007,22(3)：249-250
[49]张剑军,刘鲁明.扶正中药治疗恶性肿瘤患者正气虚弱的免疫学机理[J].中医药临床杂志,2006,18(4)：417-419
[50]张莉,张仲海,徐勤,等.扶正消瘤汤对乳腺癌患者生存质量及免疫功能影响临床研究[J].实用中医药杂志,2008,24(8)：482-483
[51]宋淑霞,吕占军.扶正、补肾及益气补肾方药对肾虚老龄小鼠免疫功能的影响[J].细胞与分子免疫学杂志,2002,18(4)：387-389,392
[52]金龙,葛争艳,刘建勋.五子衍宗丸对小鼠记忆力、免疫功能、耐缺氧及耐疲劳的影响[J].中国实验方剂学杂志,2010,16(16)：123-125
[53]董晓辉,董竞成.黄芪注射液增强树突细胞的抗肺癌作用[J].中国实验方剂学杂志,2005,11(1)：25-28
[54]应栩华,许继平,工华庆,等.河车大造胶囊改善恶性肿瘤免疫状态的临床与实验研究[J].浙江中医学院学报,1998,22(3)：39
[55]刘源,王淑玲.补肾散结方联合GP方案治疗晚期非小细胞肺癌临床疗效观察[J]中华中医药杂志,2011,26(4)：864-867
[56]周茂文,姚艳辉,肖鸿敏.首杞补肾口服液对小鼠免疫功能的影响[J].中药材,2003,26(8)：575-577
[57]毕莲,吴晓勇,陈育,等.益气养血补肾方对低免疫力大鼠免疫功能影响的实验研究[J].辽 宁中医药大学学报,2008,10(9)：157-158
[58]马骏,吴榕洲,王国骅,等.补肾软坚方与MVP方案联用治疗老年晚期肺癌32例[J].中国临床医学,2001,8(5)：506-508
[59]吕苑忠,孔庆志.半枝莲补肾合剂治疗中晚期非小细胞肺癌临床疗效研究[J].中国癌症防治杂志,2009,1(3)：232-234
[60]刘红健,秦鉴,吴国珍.健脾益气补肾法辅助化疗治疗非小细胞肺癌临床观察[J].中国中医急症,2009,18(12)：1959-1960,2016
[61]吴小明.补肾健脾中药降低中晚期肺癌化疗毒副反应效果观察[J].中医药临床杂志,2010,22(5)：394-393
[62]Hopwood P, Stephens RJ. Depression in patients with lung cancer:prevalence and risk factors derived from quality-of-life data[J]. J Clin Onco,2000,118:893～903
[63]王浩,李春波,张鹏,等.肺癌病人确诊前后抑郁症状及生活质量分析[J].中华胸心血管外科杂志,2010,26(6)：389-392
[64]王卉,朱慧,李蓓,等.肺癌患者心理及免疫功能变化的相关性研究[J].中国行为医学科学,2005,14(4)：320-321
[65]毛海婷,张玲,王芸,等.淫羊蓿甙抗癌作用机制的实验研究[J].中药材,2000,23(9)：554-556
[66]吴煜,杨宇飞,邬冬华.康莱特抗小鼠肺腺癌LA795肺转移相关基因表达谱的研究[J].中国肺癌杂志,2003,6(6)：473-476
[67]李东,姜森.中药白毛夏枯草水提液体外抗肿瘤研究[J].吉林中医药,2009,29(5)：434-435
[1]李玉林,唐建武.病理学[M].北京：人民卫生出版社,2005.182-183
[2]Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women[J]. Natl Cancer Inst,1994,86:869-70
[3]Stabile LP, Davis ALG, Gubish CT, et al. Human non small cell lung tumors and cells derived from normal lung express both estrogen receptor a and h and show biological responses to estrogen[J]. Cancer Res,2002,62:2141～2150
[4]Pietras RJ, Marquez DC, Chen H-W, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells[J]. Steroids,2005,70:372～381
[5]A.M. Hogan, D. Collins, A.W. Baird, D.C. Winter. Estrogen and gastrointestinal malignancy [J].Mol. Cell. Endocrinol.,2009,(307):19～24
[6]R. Sato, T. Suzuki, Y. Katayose, K. Miura, K. Shiiba, H. Tateno, Y. Miki, J. Akahira, Y. Kamogawa, S. Nagasaki, K. Yamamoto, T. li, S. Egawa, D.B. Evans, M. Unno, H. Sasano.Steroid sulfatase and estrogen sulfotransferase in colon carcinoma:regulators of intratumoral estrogen concentrations and potent prognostic factors.Cancer Res.,2009, (69): 914～922
[7]W. Kawabata, T. Suzuki, T. Moriya, K. Fujimori, H. Naganuma, S. Inoue, Y. Kinouchi, K. Kameyama, H. Takami, T. Shimosegawa, H. Sasano.Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders:possible in situ estrogen synthesis and actions.Mod. Pathol.,2003,(16):437～444
[8]陈名声,徐焰,郝晓柯,等.血清性激素的水平对男性肺癌患者诊断的意义[J].中国肺癌杂志,2005,8(4)：300-303
[9]苏庆军,陈建国,王一男,等.男性肺癌患者血清性激素水平的分析[J].华南国防医学杂志,2007,21(6)：13-14
[10]武翠华,罗南萍,牛爱军,等.肺癌和食管癌患者血清性激素水平的观察[J].实用医药杂志,2004,21(4)：324
[11]A. Koushik, M.E. Parent, J. Siemiatycki.Characteristics of menstruation and pregnancy and the risk of lung cancer in women[J] Int. J. Cancer,125 (2009):2428～2433
[12]Zhou XD,Cai WQ, Cao HW.Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer [J].Chin J Cancer.2002,21(3):259～262
[13]Stabile LP, Davis ALG, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and β and show biological responses to estrogen [J].Cancer Res,2002,62:2141～2150
[14]Slatore C G, Chien JW, Au DH, et al.Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study [J]. J Clin Oncol,2010,28:1540～1546
[15]顾玉兰,张子文,李璐等.肺癌患者血清性激素水平的变化及意义[J].中国实用医药,2010,5(1)：7-8
[16]苏庆军,陈建国,王一男等.男性肺癌患者血清性激素水平的分析[J].华南国防医学杂志,2007,21(6)：13-14
[17]CHEN G G, ZENG Q, TSE G M. Estrogen and its receptors incancer[J]. Med Res Rev, 2008,28 (6):954～974
[18]Salvatori L, Ravenna L, Caporuscio F, et al. Action of retinoic acid receptor on EGFR gene transactivation and breast cancer cell proliferation:Interplay with the estrogen receptor[J]. Biomed Pharmacother,2011,65(4):307～312
[19]Zhang Z, Zhou D, Lai Y, et al. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways[J]. Cancer Lett,2012,319(l):89～97
[20]Spink B C, Bennett J A, Lostritto N, et al. Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis ofMCF-7 breast cancer cells[J].Mol Carcinog,2012,16:1321～1332
[21]WEINBERG 0 K, MARQUEZ-GARBAN D C, FISHBEIN M C, et al. Aromatase inhibitors in human lung cancer therapy [J]. Cancer Res,2005,65(24):11287～11291
[22]Hillner B E. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer[J]. Cancer,2004,101 (6):1311～1322
[23]Kijima I, Itoh T, Chen S. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen[J]. J Steroid Biochem Mol Biol,2005,97(4):360～368
[24]Mccaig F M, Renshaw L, Williams L, et al. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer[J]. Breast Cancer Res Treat,2010,119(3):643～651
[25]陈宏新,贾哲浦,姜健,等.肿瘤患者外周血Th1/Th2的检测及意义[J].现代检验医学杂志,2003,18(2)：50-51
[26]孙继萍,肖伟.Th1/Th2状态与肿瘤[J].实用医药杂志,2004,21(12)：1127-1129
[27]张圣林,邱法波,吴力群.Th1/Th2偏移与恶性肿瘤关系的研究进展[J].细胞与分子免疫学杂志,2005,21(z1)：113-114,117
[28]王长印,李萍,董振芳,等.Th1/Th2细胞模式与肿瘤相关性的探讨[J].山东医药,2011,51(31)：25-26
[29]陈宏新,贾哲浦,姜健,等.肿瘤患者外周血Th1/Th2的检测及意义[J].现代检验医学杂志,2003,18(2)：50-51
[30]李志强,高建齐,谭耀驹,等.非小细胞肺癌手术治疗与Th1/Th2的漂移[J].中国误诊学杂志,2004,4(8)：1163-1165
[31]白澎,张沪生,王毓洲.肺癌患者外周血CD4+T淋巴细胞Th1/Th2分化情况检测与分析[J].首都医科大学学报,2006,27(1)：17-19
[32]赵坚强,冯建国,郭良,等.甲状腺肿瘤患者Th1/Th2漂移对自然杀伤细胞影响的临床研究[J].中国综合临床,2007,23(3)：241-243
[33]陈莉婷,Chunlin Chen,刘萍.介入治疗前后宫颈癌组织局部肿瘤瘤细胞Th1/Th2类因子表达动态变化的研究[J].现代妇产科进展,2008,17(7)：522-524
[34]辛晓玲,刘志杰,赵汝珠,等.卵巢癌患者外周血中Th1/Th2类细胞因了测定的临床研究[J].实用医学杂志,2008,24(7)：1154-11 56
[35]杜秀坤,王全生,周谨,等.胃癌根治术前后Th1/Th2比率变化的临床意义[J].河北医药,2009,31(23)：3224-3225
[36]赵晴,赵善斌,王艳峰,等.肾癌患者外周血Th1/Th2和Tcl/Tc2细胞因了的表达[J].中华临床医师杂志(电子版),2011,05(18)：5449-5451
[37]曹颖平,康明强,张旸,等.肺癌患者的Th1/Th2免疫反应状态[J].福建医科大学学报,2007,41(2)：150-152
[38]Yamazaki K, Yano T, Kameyama T, et al. Clinical s ignificanceof serum Thl/Th2 cytokines in patients with pulmonary adenocarcinoma [J]. Surgery,2002,131(1 Suppl):S236-241.
[39]Carine A P, Hamid E, Geraldine C, et al. Quantitative analys is of Th1、Th2 and TGF-cytokine expres s ion in tumor or TIL and PBL of non-small cell lung cancer patients [J]. Int J Cancer,1998,77:7～12
[40]高平,陈正贤.非小细胞肺癌肿瘤侵润淋巴细胞TH免疫失衡[J].实用医学杂志,2005,21(21)：2376-2378
[41]储大同肿瘤中医药治疗评价的新共识及其启迪[J].中国处方药,2004,29(8)：42-44.
[42]刘海涛,戴锡孟.中药扶正合剂对LA795转移性肺癌小鼠的抑瘤作用和机制研究[J].江苏中医药,2004,25(10)：56-58
[43]孙太振,郑玉玲,王祥麒.芪瑞扶正胶囊对肺癌IL-2 NK细胞活性和T细胞亚群的影响[J].中医药学刊,2004,22(12)：2229-2230
[44]田菲,贾英杰,陈军,等.扶正液对于肺癌患者的肿瘤标志物CYFRA及免疫功能的影响[J].肿瘤研究与临床,2004,16(6)：378-379
[45]梅宏,陈志昌.参芪扶正注射液对肺癌患者手术后免疫功能的调节作用[J].四川大学学报(医学版),2005,36(3)：449-450
[46]宋岚,徐朝军,黄春林,等.参芪扶正注射液对肺癌小鼠顺铂化疗后免疫功能的影响[J].实用全科医学,2007,5(11)：943-944
[47]刘扬帆,任琳莉.参芪扶正注射液对中晚期非小细胞肺癌化疗患者[J].中国当代医药,2011,18(10)：83,86.
[48]程晓东,郭峰,刘嘉湘,等.中药扶正方对小鼠Lewis肺癌的疗效及其免疫学机制的研究[J].中国中西医结合杂志,1997,17(2)：88-90
[49]安富文典.人参养荣汤的抗肿瘤作用及其作用机理[J].东京医科大学杂志,1997.55(5)：616-623
[50]杨丹丹.温肾补阳药物调节免疫的分自机制与丛因调控研究进展[J].江苏中医药,2004,25(7)：59-61
[51]杨丹丹,詹臻.温肾补阳方对实验性免疫低下小鼠胸腺免疫细胞分化影响的实验研究 [J].江苏中医药,2005,26(3)：51-53
[52]刘永惠,杨晓峰,周冬枝.肿瘤血瘀证实质及活血化瘀治则的研究[J].河北中医,2002,24(4)：252-254
[53]张亚密,徐军建.益气活血法对恶性肿瘤患者免疫功能的影响[J].陕西中医,2006,27(9)：1035-1037
[54]钟锐,苏春芝,苑静波.益气活血汤配合介入治疗原发性肝癌26例[J].陕西中医,2007,28(9)：1117-1119
[55]高芳,王红梅.扶正活血中药在恶性肿瘤化疗中的应用——附187例临床资料分析[J].中国中医急症,2007,16(10)：1194-1195
[56]于明薇,杨国旺,王笑民.化瘀丸对小鼠Lewis月市癌生长及血栓形成相关因子的干预作用[J].中国实验方剂学杂志,2011,17(17)：163-166
[57]陈培丰,雷永仲,张丽英.养阴清热法治疗晚期肺癌的机理探讨[J].浙江中医学院学报,1990,14(3)：29-32
[58]潘淑云,孙维刚,丁隽英.中药软坚散结汤治疗晚期非小细胞肺癌30例[J].辽宁中医杂志,2002,29(12)：723
[59]陈雨燕,李育宏,陈群.肺癌患者抑郁状态与细胞免疫功能关系初探[J].福建医药杂志,2006,28(5)：61-62
[60]杨智辉,王建平.癌症住院患者心理状况调查[J].中国康复医学杂志,2007,22(5)：463-465.
[61]张丰华,黄秀深,牛朝阳,等.小柴胡汤对S180荷瘤小鼠肿瘤血管生成的影响[J]中医药学刊,2004,22(2)：269--270
[62]刘矗,马丽萍,李伟权,等.滋阴疏肝汤对多囊卵巢小鼠内分泌功能的影响[J].中国中西医结合皮肤性病学杂志,2005,4(1)：29-30
[63]张丽芬,宋阿凤,王志华,等.调肾疏肝针法对乳腺增生患者内分泌、免疫功能的影响[J].中国针灸,2008,28(9)：648-652
[64]王桐生,王靓,施伶俐,等.香附理气颗粒对小鼠免疫功能影响的实验研究[J].中国现代医药杂志,2010,12(2)：30-32
[65]周立江,殷东风,潘玉真,等.肺积宁方对C57小鼠肺癌VEGF蛋白表达和生存质量的影响[J].现代肿瘤学,2009,17(6)：1042-1045
[66]钱瑞琴,杨宇,蒋文跃.理气活血中药调整应激大鼠免疫和血液流变性的机理研究[J].中国中西医结合杂志,2001,21(5)：364-366
[67]李杰,宋淑霞,吕占军.人参皂苷抗肿瘤作用的研究进展[J].中国肿瘤生物治疗杂志,2004,11(1)：61-63
[68]王卫霞,工谦.人参皂苷的免疫调节作用及其应用[J].中华中医药杂志,2005,20(4)：234-236
[69]倪劲松,辛颖,王心蕊,等.20(S)-人参皂苷Rg3对Lewis月肺癌生长及转移的抑制作用[J].肿瘤防治研究,2006,33(5)：311-313
[70]邹波峰,李康,王沈玉.艾迪注射液配合化疗治疗非小细胞肺癌的临床观察[J].实用肿瘤学杂志,2007,21(3)：268-269
[71]王迪进,陈颖兰,任剑,等.艾迪注射液配合化疗治疗晚期非小细胞肺癌的随机临床研究[J].中国肺癌杂志,2004,7(3)：247-249
[72]张爱琴,孙在典,舒琦瑾,等.艾迪注射液配合化疗治疗晚期非小细胞肺癌的临床观察[J].实用中西医结合临床,2005,5(3)：26-27
[73]胡志雄,孙书明.艾迪注射液联合NP方案治疗晚期非小细胞肺癌临床观察[J].中国临床医学,2005,12(3)：530-532
[74]白春华,鞠春梅.艾迪注射液联合NP方案治疗老年非小细胞肺癌的临床研究[J].中国老年学杂志,2005,25(12)：1535-1536
[75]卞美广,邢海燕,罗毅,等.艾迪注射液合TP方案治疗晚期非小细胞肺癌疗效观察[J].辽宁中医杂志,2007,34(2)：174-175
[76]周松晶.艾迪注射液联合化疗治疗晚期非小细胞肺癌60例[J].现代预防医学,2011,38(10)：1956-1958
[2]张培彤,于明谓,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7)：702-705
[3]张培彤,于明薇,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7)：702-705
[4]刘嘉湘.中医药维护癌症患者生存质量的作用[J].中华肿瘤杂志,2002,24(3)：309-310
[5]林丽珠,周岱翰,郑心婷.中医药提高晚期非小细胞肺癌患者生存质量的临床观察[J].中国中西医结合杂志,2006,26(5)：389-393
[6]刘源,王淑玲.补肾散结方联合GP方案治疗晚期非小细胞肺癌临床疗效观察[J].中华中医药杂志,2011,26(4)：864-867
[7]章静波,张世馥,黄东阳等.组织和细胞培养技术[M].北京：人民卫生出版社,2002,9-144
[8]符慧群,唐雪元,潘宇亮.川芍嗓和顺铂联用对小鼠Lewis扛癌生长及转移的抑制作用[J].南华大学学报医学版,2008,36(1)：46-49
[9]靳福鹏,张梅,李平等.益气养阴解毒方对小鼠Lewis肺癌生长抑制作用的实验研究[J].临床肺科杂志,2011,16(1)：72-74
[10]Zhou XD,Cai WQ, Cao HW.Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer [J].Chin J Cancer,2002,21(3):259-262
[11]Stabile LP, Davis ALG, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and (3 and show biological responses to estrogen [J].Cancer Res,2002,62:2141～2150
[12]姚榛祥,唐时森.胎儿乳腺的雌激素受体与乳腺癌[J].中华肿瘤杂志,1991,13(5)：342-343
[13]陈明伟,胡国瑛.双抗夹心法检测肺癌血清激素水平的变化[J].西安医科大学学报,1999,20(2)：202-204
[14]武翠华,罗南萍,牛爱军等.肺癌和食管癌患者血清性激素水平的观察.实用医药杂志,2004,21(4)：324-325
[15]孙继萍,肖伟.Th1/Th2状态与肿瘤[J].实用医药杂志,2004,21(12)：1127-1129
[16]张圣林,邱法波,吴力群.Th1/Th2偏移与恶性肿瘤关系的研究进展[J].细胞与分子免疫学杂志,2005,21(21)：113-114,117
[17]王长印,李萍,董振芳,等.Th1/Th2细胞模式与肿瘤相关性的探讨[J].山东医药,2011,51(31)：25-26
[18]Wynder E. L. The past, present, and future of the prevention of lung cancer. Cancer Epidemiol. Biomark. Prev.,1998,7:735～748
[19]Baldini E. H., Strauss G M. Women and lung cancer:waiting to exhale. Chest,1997,112: 229～239
[20]Shriver S. P., Bourdeau H. A., Gubish C. T., Tirpak D. L., Davis A. L., Luketich J. D., Siegfried J. M. Sex-specific expression of gastrin-releasing peptide receptor:relationship to smoking history and risk of lung cancer. J. Natl. Cancer Inst. (Bethesda),2000,92:24～33
[21]Zang E. A., Wynder E. L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl. Cancer Inst. (Bethesda),1996,88:183～192
[22]Slatore C G, Chien JW, Au DH, et al.Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study [J]. J Clin Oncol,2010,28:1540～1546
[23]岳玲.肺癌及肺癌伴男性乳房发育者血清性激素水平检测及其临床意义[J].安徽医科大学学报,1998,33(2)：140-141.
[24]陈国安,杨得昌,何积银.肺癌患者血中性激素、皮质醇及癌胚抗原水平的研究.陕西医学,1992,21(12)：710-712
[25]陈名声,徐焰,郝晓柯,等.血清性激素的水平对男性肺癌患者诊断的意义.中国肺癌杂志,2005,8：300-303
[26]顾玉兰,张子文,李璐等.肺癌患者血清性激素水平的变化及意义[J].中国实用医药,2010,5(1)：7-8
[27]徐袁秋,许会军.非小细胞肺癌患者血清性激素的变化.河北医药,2011,33(20)：3050-3052
[28]CHEN G G, ZENG Q, TSE G M. Estrogen and its receptors incancer[J]. Med Res Rev, 2008,28 (6):954～974
[29]Lu Q, Nakmura J, Savinov A, et al. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology,1996,137(7):3061～3068
[30]周向东,曹红伟,蔡文琴.男性肺癌患者外周血性激素水平的测定及其临床意义[J].中国肺癌杂志,2001,4(4)：290-292
[31]Thomas L, Doyle L, Edelman M (2005) Lung cancer in women:emerging differences in epidemiology, biology, and therapy. Chest 128:370～381
[32]Gasperino J, Rom W (2004) Gender and lung cancer. Clin Lung Cancer 5:353～359
[33]Stabile L P, Davis A L, Gubish C T, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen[J]. Cancer Res,2002,62(7):2141～2150
[34]Canver C C, Memoli V A, Vanderveer P L, et al. Sex hormone receptors in non-small-cell lung cancer in human beings[J]. J Thorac Cardiovasc Surg,1994,108(1):153～157
[35]邹建军,陈华江,高勇,等.雌激素和孕激素受体在非小细胞肺癌中的的表达[J].中国肿瘤临床,2004,31(19)：1108-1110
[36]李青山,冯威健,赵晓明,等.雌、孕激素受体与P-糖蛋白在肺癌中的表达及其意义[J].临床肿瘤学杂志,2003,8(4)：248-250
[37]闫明,陈小兵,王淑玲,等.雌激素和雄激素受体在肺癌中的表达[J].中国肺癌杂 志,2008,11(1)：126-129
[38]郑军,姚榛祥.三苯氧胺对乳腺癌细胞凋亡和耐药性的影响[J].中华肿瘤杂志,2000,22(1)：55-57
[39]刘延鹏,李玲,潘祥林,等.三苯氧胺联合化疗治疗恶性胶质瘤[J].中国神经精神疾病杂志,2007,33(8)：503-504
[40]宋丽华,肖洲生,周宏濒.植物性雌激素的研究进展[J].国外医学(药学分册),2003,30(1)：25-29
[41]张雯.植物性雌激素化学成分及其药理研究[J].中国现代实用医学杂志,2005,4(8)：50-54
[42]柳林,张玉珍,刘欣.植物性雌激素对更年期症状及癌症的临床作用[J].潍坊医学院学报,2003,25(6)：462-463
[43]王妹妹,范林军.植物性雌激素摄入与乳腺癌的关联[J].中华乳腺病杂志(电子版),2008,2(2)：238-248
[44]夏仲元,潘琳,李鸿,等.疏肝通络方干预乳腺增生大鼠的实验研究[J].北京中医药大学学报,2009,32(12)：834-838
[45]Yamamura M, Modlin RL, Ohmen JD, et al. Local exp ression of anti-inflammatory cytokines in cancer. [J] Clin Invest,1993,91:1005～1010
[46]Huang M, W ang J, L ee P, et al. Human non small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res,1995,55:3847-3853
[47]刘杰,田志刚,冯进波,等.人肿瘤细胞中Th2类细胞因子的强势表达[J].中华肿瘤杂志,1998,(2)：105
[48]王敬然,董英辉.生物免疫制剂及参芪扶正注射液对NF-κB活性的影响[J].实用肿瘤杂志,2007,22(3)：249-250
[49]张剑军,刘鲁明.扶正中药治疗恶性肿瘤患者正气虚弱的免疫学机理[J].中医药临床杂志,2006,18(4)：417-419
[50]张莉,张仲海,徐勤,等.扶正消瘤汤对乳腺癌患者生存质量及免疫功能影响临床研究[J].实用中医药杂志,2008,24(8)：482-483
[51]宋淑霞,吕占军.扶正、补肾及益气补肾方药对肾虚老龄小鼠免疫功能的影响[J].细胞与分子免疫学杂志,2002,18(4)：387-389,392
[52]金龙,葛争艳,刘建勋.五子衍宗丸对小鼠记忆力、免疫功能、耐缺氧及耐疲劳的影响[J].中国实验方剂学杂志,2010,16(16)：123-125
[53]董晓辉,董竞成.黄芪注射液增强树突细胞的抗肺癌作用[J].中国实验方剂学杂志,2005,11(1)：25-28
[54]应栩华,许继平,工华庆,等.河车大造胶囊改善恶性肿瘤免疫状态的临床与实验研究[J].浙江中医学院学报,1998,22(3)：39
[55]刘源,王淑玲.补肾散结方联合GP方案治疗晚期非小细胞肺癌临床疗效观察[J]中华中医药杂志,2011,26(4)：864-867
[56]周茂文,姚艳辉,肖鸿敏.首杞补肾口服液对小鼠免疫功能的影响[J].中药材,2003,26(8)：575-577
[57]毕莲,吴晓勇,陈育,等.益气养血补肾方对低免疫力大鼠免疫功能影响的实验研究[J].辽 宁中医药大学学报,2008,10(9)：157-158
[58]马骏,吴榕洲,王国骅,等.补肾软坚方与MVP方案联用治疗老年晚期肺癌32例[J].中国临床医学,2001,8(5)：506-508
[59]吕苑忠,孔庆志.半枝莲补肾合剂治疗中晚期非小细胞肺癌临床疗效研究[J].中国癌症防治杂志,2009,1(3)：232-234
[60]刘红健,秦鉴,吴国珍.健脾益气补肾法辅助化疗治疗非小细胞肺癌临床观察[J].中国中医急症,2009,18(12)：1959-1960,2016
[61]吴小明.补肾健脾中药降低中晚期肺癌化疗毒副反应效果观察[J].中医药临床杂志,2010,22(5)：394-393
[62]Hopwood P, Stephens RJ. Depression in patients with lung cancer:prevalence and risk factors derived from quality-of-life data[J]. J Clin Onco,2000,118:893～903
[63]王浩,李春波,张鹏,等.肺癌病人确诊前后抑郁症状及生活质量分析[J].中华胸心血管外科杂志,2010,26(6)：389-392
[64]王卉,朱慧,李蓓,等.肺癌患者心理及免疫功能变化的相关性研究[J].中国行为医学科学,2005,14(4)：320-321
[65]毛海婷,张玲,王芸,等.淫羊蓿甙抗癌作用机制的实验研究[J].中药材,2000,23(9)：554-556
[66]吴煜,杨宇飞,邬冬华.康莱特抗小鼠肺腺癌LA795肺转移相关基因表达谱的研究[J].中国肺癌杂志,2003,6(6)：473-476
[67]李东,姜森.中药白毛夏枯草水提液体外抗肿瘤研究[J].吉林中医药,2009,29(5)：434-435
[1]李玉林,唐建武.病理学[M].北京：人民卫生出版社,2005.182-183
[2]Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women[J]. Natl Cancer Inst,1994,86:869-70
[3]Stabile LP, Davis ALG, Gubish CT, et al. Human non small cell lung tumors and cells derived from normal lung express both estrogen receptor a and h and show biological responses to estrogen[J]. Cancer Res,2002,62:2141～2150
[4]Pietras RJ, Marquez DC, Chen H-W, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells[J]. Steroids,2005,70:372～381
[5]A.M. Hogan, D. Collins, A.W. Baird, D.C. Winter. Estrogen and gastrointestinal malignancy [J].Mol. Cell. Endocrinol.,2009,(307):19～24
[6]R. Sato, T. Suzuki, Y. Katayose, K. Miura, K. Shiiba, H. Tateno, Y. Miki, J. Akahira, Y. Kamogawa, S. Nagasaki, K. Yamamoto, T. li, S. Egawa, D.B. Evans, M. Unno, H. Sasano.Steroid sulfatase and estrogen sulfotransferase in colon carcinoma:regulators of intratumoral estrogen concentrations and potent prognostic factors.Cancer Res.,2009, (69): 914～922
[7]W. Kawabata, T. Suzuki, T. Moriya, K. Fujimori, H. Naganuma, S. Inoue, Y. Kinouchi, K. Kameyama, H. Takami, T. Shimosegawa, H. Sasano.Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders:possible in situ estrogen synthesis and actions.Mod. Pathol.,2003,(16):437～444
[8]陈名声,徐焰,郝晓柯,等.血清性激素的水平对男性肺癌患者诊断的意义[J].中国肺癌杂志,2005,8(4)：300-303
[9]苏庆军,陈建国,王一男,等.男性肺癌患者血清性激素水平的分析[J].华南国防医学杂志,2007,21(6)：13-14
[10]武翠华,罗南萍,牛爱军,等.肺癌和食管癌患者血清性激素水平的观察[J].实用医药杂志,2004,21(4)：324
[11]A. Koushik, M.E. Parent, J. Siemiatycki.Characteristics of menstruation and pregnancy and the risk of lung cancer in women[J] Int. J. Cancer,125 (2009):2428～2433
[12]Zhou XD,Cai WQ, Cao HW.Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer [J].Chin J Cancer.2002,21(3):259～262
[13]Stabile LP, Davis ALG, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and β and show biological responses to estrogen [J].Cancer Res,2002,62:2141～2150
[14]Slatore C G, Chien JW, Au DH, et al.Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study [J]. J Clin Oncol,2010,28:1540～1546
[15]顾玉兰,张子文,李璐等.肺癌患者血清性激素水平的变化及意义[J].中国实用医药,2010,5(1)：7-8
[16]苏庆军,陈建国,王一男等.男性肺癌患者血清性激素水平的分析[J].华南国防医学杂志,2007,21(6)：13-14
[17]CHEN G G, ZENG Q, TSE G M. Estrogen and its receptors incancer[J]. Med Res Rev, 2008,28 (6):954～974
[18]Salvatori L, Ravenna L, Caporuscio F, et al. Action of retinoic acid receptor on EGFR gene transactivation and breast cancer cell proliferation:Interplay with the estrogen receptor[J]. Biomed Pharmacother,2011,65(4):307～312
[19]Zhang Z, Zhou D, Lai Y, et al. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways[J]. Cancer Lett,2012,319(l):89～97
[20]Spink B C, Bennett J A, Lostritto N, et al. Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis ofMCF-7 breast cancer cells[J].Mol Carcinog,2012,16:1321～1332
[21]WEINBERG 0 K, MARQUEZ-GARBAN D C, FISHBEIN M C, et al. Aromatase inhibitors in human lung cancer therapy [J]. Cancer Res,2005,65(24):11287～11291
[22]Hillner B E. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer[J]. Cancer,2004,101 (6):1311～1322
[23]Kijima I, Itoh T, Chen S. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen[J]. J Steroid Biochem Mol Biol,2005,97(4):360～368
[24]Mccaig F M, Renshaw L, Williams L, et al. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer[J]. Breast Cancer Res Treat,2010,119(3):643～651
[25]陈宏新,贾哲浦,姜健,等.肿瘤患者外周血Th1/Th2的检测及意义[J].现代检验医学杂志,2003,18(2)：50-51
[26]孙继萍,肖伟.Th1/Th2状态与肿瘤[J].实用医药杂志,2004,21(12)：1127-1129
[27]张圣林,邱法波,吴力群.Th1/Th2偏移与恶性肿瘤关系的研究进展[J].细胞与分子免疫学杂志,2005,21(z1)：113-114,117
[28]王长印,李萍,董振芳,等.Th1/Th2细胞模式与肿瘤相关性的探讨[J].山东医药,2011,51(31)：25-26
[29]陈宏新,贾哲浦,姜健,等.肿瘤患者外周血Th1/Th2的检测及意义[J].现代检验医学杂志,2003,18(2)：50-51
[30]李志强,高建齐,谭耀驹,等.非小细胞肺癌手术治疗与Th1/Th2的漂移[J].中国误诊学杂志,2004,4(8)：1163-1165
[31]白澎,张沪生,王毓洲.肺癌患者外周血CD4+T淋巴细胞Th1/Th2分化情况检测与分析[J].首都医科大学学报,2006,27(1)：17-19
[32]赵坚强,冯建国,郭良,等.甲状腺肿瘤患者Th1/Th2漂移对自然杀伤细胞影响的临床研究[J].中国综合临床,2007,23(3)：241-243
[33]陈莉婷,Chunlin Chen,刘萍.介入治疗前后宫颈癌组织局部肿瘤瘤细胞Th1/Th2类因子表达动态变化的研究[J].现代妇产科进展,2008,17(7)：522-524
[34]辛晓玲,刘志杰,赵汝珠,等.卵巢癌患者外周血中Th1/Th2类细胞因了测定的临床研究[J].实用医学杂志,2008,24(7)：1154-11 56
[35]杜秀坤,王全生,周谨,等.胃癌根治术前后Th1/Th2比率变化的临床意义[J].河北医药,2009,31(23)：3224-3225
[36]赵晴,赵善斌,王艳峰,等.肾癌患者外周血Th1/Th2和Tcl/Tc2细胞因了的表达[J].中华临床医师杂志(电子版),2011,05(18)：5449-5451
[37]曹颖平,康明强,张旸,等.肺癌患者的Th1/Th2免疫反应状态[J].福建医科大学学报,2007,41(2)：150-152
[38]Yamazaki K, Yano T, Kameyama T, et al. Clinical s ignificanceof serum Thl/Th2 cytokines in patients with pulmonary adenocarcinoma [J]. Surgery,2002,131(1 Suppl):S236-241.
[39]Carine A P, Hamid E, Geraldine C, et al. Quantitative analys is of Th1、Th2 and TGF-cytokine expres s ion in tumor or TIL and PBL of non-small cell lung cancer patients [J]. Int J Cancer,1998,77:7～12
[40]高平,陈正贤.非小细胞肺癌肿瘤侵润淋巴细胞TH免疫失衡[J].实用医学杂志,2005,21(21)：2376-2378
[41]储大同肿瘤中医药治疗评价的新共识及其启迪[J].中国处方药,2004,29(8)：42-44.
[42]刘海涛,戴锡孟.中药扶正合剂对LA795转移性肺癌小鼠的抑瘤作用和机制研究[J].江苏中医药,2004,25(10)：56-58
[43]孙太振,郑玉玲,王祥麒.芪瑞扶正胶囊对肺癌IL-2 NK细胞活性和T细胞亚群的影响[J].中医药学刊,2004,22(12)：2229-2230
[44]田菲,贾英杰,陈军,等.扶正液对于肺癌患者的肿瘤标志物CYFRA及免疫功能的影响[J].肿瘤研究与临床,2004,16(6)：378-379
[45]梅宏,陈志昌.参芪扶正注射液对肺癌患者手术后免疫功能的调节作用[J].四川大学学报(医学版),2005,36(3)：449-450
[46]宋岚,徐朝军,黄春林,等.参芪扶正注射液对肺癌小鼠顺铂化疗后免疫功能的影响[J].实用全科医学,2007,5(11)：943-944
[47]刘扬帆,任琳莉.参芪扶正注射液对中晚期非小细胞肺癌化疗患者[J].中国当代医药,2011,18(10)：83,86.
[48]程晓东,郭峰,刘嘉湘,等.中药扶正方对小鼠Lewis肺癌的疗效及其免疫学机制的研究[J].中国中西医结合杂志,1997,17(2)：88-90
[49]安富文典.人参养荣汤的抗肿瘤作用及其作用机理[J].东京医科大学杂志,1997.55(5)：616-623
[50]杨丹丹.温肾补阳药物调节免疫的分自机制与丛因调控研究进展[J].江苏中医药,2004,25(7)：59-61
[51]杨丹丹,詹臻.温肾补阳方对实验性免疫低下小鼠胸腺免疫细胞分化影响的实验研究 [J].江苏中医药,2005,26(3)：51-53
[52]刘永惠,杨晓峰,周冬枝.肿瘤血瘀证实质及活血化瘀治则的研究[J].河北中医,2002,24(4)：252-254
[53]张亚密,徐军建.益气活血法对恶性肿瘤患者免疫功能的影响[J].陕西中医,2006,27(9)：1035-1037
[54]钟锐,苏春芝,苑静波.益气活血汤配合介入治疗原发性肝癌26例[J].陕西中医,2007,28(9)：1117-1119
[55]高芳,王红梅.扶正活血中药在恶性肿瘤化疗中的应用——附187例临床资料分析[J].中国中医急症,2007,16(10)：1194-1195
[56]于明薇,杨国旺,王笑民.化瘀丸对小鼠Lewis月市癌生长及血栓形成相关因子的干预作用[J].中国实验方剂学杂志,2011,17(17)：163-166
[57]陈培丰,雷永仲,张丽英.养阴清热法治疗晚期肺癌的机理探讨[J].浙江中医学院学报,1990,14(3)：29-32
[58]潘淑云,孙维刚,丁隽英.中药软坚散结汤治疗晚期非小细胞肺癌30例[J].辽宁中医杂志,2002,29(12)：723
[59]陈雨燕,李育宏,陈群.肺癌患者抑郁状态与细胞免疫功能关系初探[J].福建医药杂志,2006,28(5)：61-62
[60]杨智辉,王建平.癌症住院患者心理状况调查[J].中国康复医学杂志,2007,22(5)：463-465.
[61]张丰华,黄秀深,牛朝阳,等.小柴胡汤对S180荷瘤小鼠肿瘤血管生成的影响[J]中医药学刊,2004,22(2)：269--270
[62]刘矗,马丽萍,李伟权,等.滋阴疏肝汤对多囊卵巢小鼠内分泌功能的影响[J].中国中西医结合皮肤性病学杂志,2005,4(1)：29-30
[63]张丽芬,宋阿凤,王志华,等.调肾疏肝针法对乳腺增生患者内分泌、免疫功能的影响[J].中国针灸,2008,28(9)：648-652
[64]王桐生,王靓,施伶俐,等.香附理气颗粒对小鼠免疫功能影响的实验研究[J].中国现代医药杂志,2010,12(2)：30-32
[65]周立江,殷东风,潘玉真,等.肺积宁方对C57小鼠肺癌VEGF蛋白表达和生存质量的影响[J].现代肿瘤学,2009,17(6)：1042-1045
[66]钱瑞琴,杨宇,蒋文跃.理气活血中药调整应激大鼠免疫和血液流变性的机理研究[J].中国中西医结合杂志,2001,21(5)：364-366
[67]李杰,宋淑霞,吕占军.人参皂苷抗肿瘤作用的研究进展[J].中国肿瘤生物治疗杂志,2004,11(1)：61-63
[68]王卫霞,工谦.人参皂苷的免疫调节作用及其应用[J].中华中医药杂志,2005,20(4)：234-236
[69]倪劲松,辛颖,王心蕊,等.20(S)-人参皂苷Rg3对Lewis月肺癌生长及转移的抑制作用[J].肿瘤防治研究,2006,33(5)：311-313
[70]邹波峰,李康,王沈玉.艾迪注射液配合化疗治疗非小细胞肺癌的临床观察[J].实用肿瘤学杂志,2007,21(3)：268-269
[71]王迪进,陈颖兰,任剑,等.艾迪注射液配合化疗治疗晚期非小细胞肺癌的随机临床研究[J].中国肺癌杂志,2004,7(3)：247-249
[72]张爱琴,孙在典,舒琦瑾,等.艾迪注射液配合化疗治疗晚期非小细胞肺癌的临床观察[J].实用中西医结合临床,2005,5(3)：26-27
[73]胡志雄,孙书明.艾迪注射液联合NP方案治疗晚期非小细胞肺癌临床观察[J].中国临床医学,2005,12(3)：530-532
[74]白春华,鞠春梅.艾迪注射液联合NP方案治疗老年非小细胞肺癌的临床研究[J].中国老年学杂志,2005,25(12)：1535-1536
[75]卞美广,邢海燕,罗毅,等.艾迪注射液合TP方案治疗晚期非小细胞肺癌疗效观察[J].辽宁中医杂志,2007,34(2)：174-175
[76]周松晶.艾迪注射液联合化疗治疗晚期非小细胞肺癌60例[J].现代预防医学,2011,38(10)：1956-1958